The Ovarian Cancer Research Fund, Inc.
Last Modified: November 1, 2001
|Surviving Ovarian Cancer
52 minutes, 12 seconds
Oct 13, 2011 - For women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, is associated with significantly better overall survival, progression-free survival, and chemotherapy response than BRCA wild-type, according to a study published in the Oct. 12 issue of the Journal of the American Medical Association.